Last reviewed · How we verify
Delgocitinib cream
Delgocitinib is a JAK inhibitor that suppresses inflammatory cytokine signaling in immune cells to reduce skin inflammation and itching in atopic dermatitis.
Delgocitinib is a JAK inhibitor that suppresses inflammatory cytokine signaling in immune cells to reduce skin inflammation and itching in atopic dermatitis. Used for Atopic dermatitis (topical cream formulation).
At a glance
| Generic name | Delgocitinib cream |
|---|---|
| Also known as | LEO 124249 cream |
| Sponsor | LEO Pharma |
| Drug class | JAK inhibitor |
| Target | JAK1, JAK2, JAK3, TYK2 |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Delgocitinib selectively inhibits Janus kinase (JAK) enzymes, which are intracellular signaling proteins that mediate the effects of inflammatory cytokines like IL-4, IL-13, and IFN-γ. By blocking JAK signaling in T cells and other immune cells in the skin, it reduces the production of inflammatory mediators and dampens the aberrant immune response characteristic of atopic dermatitis. This leads to decreased inflammation, pruritus, and skin barrier dysfunction.
Approved indications
- Atopic dermatitis (topical cream formulation)
Common side effects
- Application site reactions (erythema, irritation)
- Headache
- Nasopharyngitis
Key clinical trials
- Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris (PHASE2)
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis (PHASE2)
- A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus (PHASE3)
- The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch (NA)
- A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema (PHASE3)
- Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (PHASE3)
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema (PHASE3)
- Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Delgocitinib cream CI brief — competitive landscape report
- Delgocitinib cream updates RSS · CI watch RSS
- LEO Pharma portfolio CI